Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-CS6 BSIgG is a hyperimmune bovine serum immunoglobulin G preparation generated by immunizing cattle with the colonization factor antigen CS6 from enterotoxigenic *Escherichia coli* (ETEC). The resulting antibodies are purified from bovine serum and administered orally as a passive prophylactic agent to prevent ETEC-induced diarrhea. The mechanism of action involves binding to the CS6 colonization factor on ETEC, theoretically blocking bacterial adherence to intestinal epithelial cells and preventing infection. In clinical studies, anti-CS6 BSIgG was well tolerated but did not demonstrate significant efficacy in preventing moderate-severe diarrhea following challenge with CS6-expressing ETEC strain B7A[1][3][4][5]. The product is developed and manufactured by SAB Biotherapeutics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-CS6 BSIgG.